The authors have noticed an error at the end of the Outcomes paragraph in the Methods section, where it currently reads ‘COVID-19-related mortality, defined as a death in ONS mortality data with COVID-19 recorded as a cause of death, or an in-hospital death during a COVID-19 hospitalisation.’ This should be replaced with ‘COVID-19-related mortality, defined as a death in ONS mortality data with COVID-19 recorded as a cause of death.’
. 2024 Jul 25;44:101008. doi: 10.1016/j.lanepe.2024.101008
Corrigendum to ‘Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study’ [The Lancet Regional Health – Europe 35 (2023) 100747]
Rachael A Evans
a, Sabada Dube
b, Yi Lu
c, Mark Yates
d, Sofie Arnetorp
e, Eleanor Barnes
f, Samira Bell
g, Lucy Carty
h, Kathryn Evans
i, Sophie Graham
c, Nahila Justo
j, Paul Moss
k,l, Sudhir Venkatesan
m, Renata Yokota
n, Catia Ferreira
o, Richard McNulty
p, Sylvia Taylor
q, Jennifer K Quint
r,∗
Rachael A Evans
aDepartment of Respiratory Sciences, University of Leicester, Leicester, United Kingdom
Find articles by Rachael A Evans
Sabada Dube
bAstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom
Find articles by Sabada Dube
Mark Yates
dData Analytics - Real World Evidence, Evidera, London, United Kingdom
Find articles by Mark Yates
Sofie Arnetorp
eVaccines and Immune Therapies, Global Market Access and Pricing, AstraZeneca R&D, 431 83, Mölndal, Sweden
Find articles by Sofie Arnetorp
Eleanor Barnes
fNuffield Department of Medicine, University of Oxford, OUH Hospital NHS Trust, Oxford, United Kingdom
Find articles by Eleanor Barnes
Samira Bell
gPopulation Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, Scotland, United Kingdom
Find articles by Samira Bell
Lucy Carty
hMedical and Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
Find articles by Lucy Carty
Sophie Graham
cEvidera, The Ark, 201 Talgarth Road, London, W6 8BJ, United Kingdom
Find articles by Sophie Graham
Nahila Justo
jIntegrated Solutions – Real World Evidence, Evidera, Stockholm, Sweden
Find articles by Nahila Justo
Paul Moss
kInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
lUniversity Hospitals Birmingham, NHS Foundation Trust, Birmingham, United Kingdom
Find articles by Paul Moss
Sudhir Venkatesan
mMedical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
Find articles by Sudhir Venkatesan
Catia Ferreira
oAstraZeneca LP, 1800 Concord Pike, Wilmington, DE, 19850-5437, USA
Find articles by Catia Ferreira
Richard McNulty
pMedical Affairs, AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom
Find articles by Richard McNulty
Sylvia Taylor
qMedical Evidence, AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom
Find articles by Sylvia Taylor
Jennifer K Quint
rNational Heart & Lung Institute, Imperial College London, United Kingdom
Find articles by Jennifer K Quint
aDepartment of Respiratory Sciences, University of Leicester, Leicester, United Kingdom
bAstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom
cEvidera, The Ark, 201 Talgarth Road, London, W6 8BJ, United Kingdom
dData Analytics - Real World Evidence, Evidera, London, United Kingdom
eVaccines and Immune Therapies, Global Market Access and Pricing, AstraZeneca R&D, 431 83, Mölndal, Sweden
fNuffield Department of Medicine, University of Oxford, OUH Hospital NHS Trust, Oxford, United Kingdom
gPopulation Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, Scotland, United Kingdom
hMedical and Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
iEvidera, Waltham, MA 02451, United States
jIntegrated Solutions – Real World Evidence, Evidera, Stockholm, Sweden
kInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
lUniversity Hospitals Birmingham, NHS Foundation Trust, Birmingham, United Kingdom
mMedical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
nP95, Leuven, Belgium
oAstraZeneca LP, 1800 Concord Pike, Wilmington, DE, 19850-5437, USA
pMedical Affairs, AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom
qMedical Evidence, AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom
rNational Heart & Lung Institute, Imperial College London, United Kingdom
∗
Corresponding author. j.quint@imperial.ac.uk
Collection date 2024 Sep.
© 2024 The Author(s)
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PMCID: PMC11326950 PMID: 39155983
This corrects the article "Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study" in volume 35, 100747.